Lotus launches the 1st generic of Vinorelbine oral formulation in Taiwan

Source: Lotus Pharmaceuticals

Taiwan is the largest market in the world for Vinorelbine soft gel capsule oral formulation – according to IQVIA data, the total sales in Taiwan for 2020 were approximately US$26 million with a 3-year CAGR of 2.4%.  

Lotus’s Vinorelbine soft gel capsule is the first and only approved so far generic product in Taiwan with already successful listing in major medical center.

Lotus is the only company in the world, which is currently commercializing generic Vinorelbine soft gel formulation in 19 countries including Taiwan, United Kingdom, Italy, Germany, France, Switzerland, Poland, Bangladesh, etc. via global partners

Lotus Pharmaceutical (1795:TT), a multinational pharmaceutical company, today announced that it has launched the first generic Vinorelbine soft gel (equivalent to Navelbine®) in Taiwan, the largest market in the world for the soft gel formulation. This is also currently the only approved generic Vinorelbine soft gel in the market and both its 20mg and 30mg have been successfully listed in Taipei Medical University Hospital, one of the leading medical centers in Taiwan, and Wan Fang Hospital as well as Shuang Ho Hospital since January 2022.

The indications of Vinorelbine soft gel include breast cancer and non-small cell lung cancer (NSCLC). According to IQVIA data, the total sales of Vinorelbine soft gel worldwide were approximately US$160 million in 2020, among which Taiwan is the largest market with 2-3% growth rate a year. It is estimated that there are 3,200 patients a year in Taiwan being treated by vinorelbine and the medical cost currently is about NT$240,000 per year per person.

Petar Vazharov, Chief Executive Officer of Lotus, said: “As a global leader in the development of oral oncology products, Lotus is proud to announce Vinorelbine soft gel capsule launch in Taiwan – the largest market of Vinorelbine oral formulation in the world. The launch of such complex product already in 19 countries is a major testimonial for the capabilities of Lotus R&D, manufacturing & supply chain management, and regulatory teams. We are pleased to expand access to our high-quality oral oncology products to patients worldwide.”

Following the successful launch in the first medical center, Lotus commercial team in Taiwan will accelerate the formulary listing in the hospitals and target to achieve 40% coverage among all the hospitals. The Company is confident that Vinorelbine soft gel formulation will become a backbone of Lotus’s oncology franchise in Taiwan and create valuable synergies among the oncology portfolio.

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
© 2024 Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978